打开APP

葛兰素史克将继续心血管药物darapladib的研究

  1. darapladib
  2. 心血管疾病
  3. 葛兰素史克

来源:生物谷 2014-04-09 19:03

在此前刚刚结束的darapladib的第一个临床三期研究阶段中,darapladib与对照组相比未能明显推迟慢性心血管疾病患者首次病发的时间。不过由于实验组的病发次数要少于安慰剂对照组的病发次数,研究人员认为这种药物可能还是有一线希望的。

2014年4月1日讯 /生物谷BIOON/ --在药物研发过程中,无论一种药物的三期研究数据有多么糟糕,研究人员都会试图找到其中的闪光点并加以放大。葛兰素史克的心血管疾病药物darapladib研究团队似乎就印证着这一说法。在此前刚刚结束的darapladib的第一个临床三期研究阶段中,darapladib与对照组相比未能明显推迟慢性心血管疾病患者首次病发的时间。不过由于实验组的病发次数要少于安慰剂对照组的病发次数,研究人员认为这种药物可能还是有一线希望的。

在这周末举行的American College of Cardiology meeting上,负责darapladib研究的Dr. Harvey White显然将这一信号当做最后的一根稻草,他表示这表明darapladib至少可能具有改善心血管疾病患者病情的作用。但是最终结果如何,葛兰素史克公司还需要用事实说话。(生物谷Bioon.com)

详细英文报道:

No matter how badly a drug fails in Phase III, investigators and the companies that employ them often bend over backward to highlight any positive sign of efficacy, no matter how weak the signal. And GlaxoSmithKline's team at the American College of Cardiology meeting over the weekend was in full spin mode with their heart drug darapladib.

Once considered one of the most innovative and promising therapies in the Glaxo's ($GSK) pipeline, darapladib failed its first big Phase III test, losing a considerable amount of luster. On Sunday, investigators spelled out the data, which demonstrated clearly that darapladib looked a lot like a placebo when it came to the primary endpoint: time to the occurrence of the first major cardiac event for patients suffering from chronic coronary disease. There was no difference in mortality, but if you take a Panglossian perspective there was a slight, possible benefit in the number of major coronary events--9.3% in the darapladib group over 3.7 years and 10.3% for the placebo arm. The p value was 0.045, indicating "nominal" significance.

"Similar effects were observed for the composite of total coronary events, which occurred in 14.9% of patients on darapladib versus 16.1% on placebo," according to GSK's release.

That's not a silver lining. Perhaps it's more like a tin lining. But it was enough to warrant some hard spinning at the conference. And GlaxoSmithKline CEO Andrew Witty, while a little more reticent, helped support the upbeat reading of the results on Monday, telling Reuters that he saw "interesting potential signals" in the study, adding that the jury's still out on the drug's potential success.

"In the STABILITY study, the lack of effect on stroke was disappointing but not unexpected given the emerging epidemiology data," said Dr. Harvey White, who co-chaired the study, in a statement. "While the study didn't meet its primary endpoint, the effects of darapladib on the reduction of coronary events are of potential interest. These findings take us a step further towards defining which patients may benefit from treatment with darapladib."

White was even more pumped in an interview with Reuters.

"I'm convinced there is a signal here of efficacy," White told Reuters. The Phase III failure of darapladib against a sugar pill might have been influenced by the great care all the patients were given--which at least offers another lesson on the benefits of great care for heart patients--as well as the drug's specific inability to prevent strokes.

"There are some interesting potential signals in the secondary endpoints but an awful lot about what we've got here is going to depend on what we see on the second study," Witty told Reuters on Monday. "I think it is still an open question as to whether we've got something (that works) or not." Witty helped engineer the $3.6 billion acquisition in 2012 of Human Genome Sciences and darapladib.

GlaxoSmithKline has generally been quite open about its successes and failures, with a string of significant new drug approvals to its credit over the past year. Another Phase III study of darapladib is ongoing in patients treated within 30 days of a heart attack. So far, though, the hardcore optimists for this drug have apparently been reduced to a group of Glaxo insiders.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->